Dual Specific Immunotoxin for Brain Tumor Therapy

We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.

Patents:
US 20,090,269,343

Inventor(s): BIGNER DARELL [US]; KUAN CHIEN-TSUN [US]; PASTAN IRA H [US]; PEGRAM CHARLES N [US]

Type of Offer: Licensing



« More Medical Patents

---